Channelchek - Looking for the next apple? This is the orchard.

ZOMDF

$0.08

(-0.41%)

FLWS

$4.08

(1.49%)

ACCO

$4.3

(0.47%)

ARLP

$26.07

(1.56%)

AUIAF

$0.12

(-9.09%)

AZZ

$143.51

(-1.99%)

BTBT

$1.4

(-3.45%)

BTM

$0.49

(0%)

CVKD

$1.64

(-4.09%)

LCE:CA

$0.27

(-5.36%)

COCP

$1.15

(6.02%)

CDRO

$9.02

(0.33%)

CVGI

$3.12

(-4.88%)

LODE

$3.43

(0%)

CMTL

$1.73

(-1.14%)

CNDT

$1.46

(2.1%)

CXW

$31.99

(-1.27%)

CMLS

$0.01

(0%)

DRCT

$2.62

(0%)

DLHC

$4.56

(0.88%)

SSP

$3.46

(4.85%)

ELDN

$3.55

(-1.93%)

EVC

$8.43

(0.12%)

EDRY

$43.29

(4.33%)

ESEA

$74.55

(2.38%)

FAT

$0.16

(0%)

RAIL

$7.22

(0.84%)

GDEV

$10.67

(-7.54%)

GOVX

$0.59

(-8.58%)

GOCO

$0.3

(0%)

GHM

$104.81

(-5.72%)

GLDD

$17

(0%)

GYRE

$7.58

(-1.88%)

HMENF

$1.95

(-0.52%)

III

$4.95

(0.41%)

IPOOF

$12.3

(2.41%)

KELYA

$16.53

(0.64%)

KTOS

$60.56

(-2.31%)

LUCK

$6.67

(1.06%)

MAIA

$1.39

(1.46%)

MGROF

$0.31

(0%)

NTRB

$3.55

(2.9%)

OCGN

$1.48

(10.45%)

PERF

$1.86

(-1.06%)

QMCI

$0.16

(6.67%)

RGP

$4.42

(3.27%)

SGA

$9.42

(0.21%)

SHWZ

(0%)

SHIP

$16.89

(-0.65%)

SLQT

$0.78

(2.81%)

SKYX

$1.16

(-1.28%)

SNAL

$2.96

(-1.66%)

GEO

$30.68

(-0.74%)

ODP

$28

(0%)

TNXP

$12.73

(0.55%)

TSQ

$5.77

(1.05%)

TZOO

$6.88

(-1.71%)

UNCY

$5.58

(-0.89%)

VVX

$82.51

(1.29%)

VNCE

$6.09

(1.16%)

XELB

$0.7

(-27.65%)

ZOMDF

$0.08

(-0.41%)

FLWS

$4.08

(1.49%)

channelchek-in

‌

8/19/2026

Moderna Doubled Today on a Cancer Vaccine Breakthrough

Moderna (Nasdaq: MRNA) shares more than doubled Wednesday after the company and Merck (NYSE: MRK) announced their personalized mRNA cancer vaccine met its primary and key secondary endpoints in a pivotal Phase 3 trial, the first positive late-stage result ever recorded for an individualized neoantigen cancer therapy and for any mRNA-based cancer treatment. The rally lifted biotech stocks broadly, with investors treating the result as validation for an entirely new category of oncology treatment that has been in development for more than a decade.

3 min read